The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZBH | -1.46% | -22.99% | -5.09% | +300% |
| S&P | +15.06% | +95.03% | +14.29% | +466% |
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
As elective surgery candidates return to operating rooms, revenue will ramp up.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.08B | 7.0% |
| Gross Profit | $1.31B | 7.2% |
| Gross Margin | 63.08% | 0.1% |
| Market Cap | $18.05B | -19.2% |
| Market Cap / Employee | $1.06M | 0.0% |
| Employees | 17K | -5.6% |
| Net Income | $153.40M | -36.9% |
| EBITDA | $659.30M | 5.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $556.90M | 32.6% |
| Accounts Receivable | $1.61B | 13.6% |
| Inventory | 2.5K | 3.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.75B | 70.7% |
| Short Term Debt | $820.00M | -56.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.71% | -0.9% |
| Return On Invested Capital | 2.86% | -0.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $247.60M | -1.6% |
| Operating Free Cash Flow | $378.20M | 2.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 20.57 | 23.81 | 25.08 | 22.21 | -1.83% |
| Price to Book | 1.74 | 1.70 | 1.81 | 1.46 | -17.82% |
| Price to Sales | 2.89 | 2.75 | 2.94 | 2.31 | -22.44% |
| Price to Tangible Book Value | -27.97 | -17.53 | -20.84 | -17.00 | -29.34% |
| Price to Free Cash Flow TTM | 24.32 | 24.57 | 21.56 | 17.28 | -39.91% |
| Enterprise Value to EBITDA | 49.87 | 38.73 | 49.28 | 38.09 | -14.74% |
| Free Cash Flow Yield | 4.1% | 4.1% | 4.6% | 5.8% | 66.42% |
| Return on Equity | 8.7% | 7.2% | 7.3% | 6.5% | -17.93% |
| Total Debt | $6.45B | $6.39B | $7.18B | $7.57B | 29.78% |
ZBH earnings call for the period ending September 30, 2021.
ZBH earnings call for the period ending June 30, 2021.
ZBH earnings call for the period ending March 31, 2021.
ZBH earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
